ESPERION THERAPEUTICS INC
ESPRNASDAQ🏆 #2536 by market capEarnings Nov 4US Equity
$3.18▲ $0.00 (+0.00%)
Live1h—
24h▲ 0.0%
7d▼ 0.3%
14d▼ 0.3%
30d▼ 0.3%
1y▲ 77.2%
🏦Market Cap
$819M
Small Cap
📈Revenue Growth (YoY)
+61.1%
High Growth
📊Gross Margin
68.4%
High
💵FCF Margin
10.8%
Healthy
⚖️P/S Ratio
2.0x
Cheap
Otter Score
50
Weak
📊
Analyst Ratings
Price
$3.18
Total
25
Raised
2
Lowered
9
Avg PT
$3.19
H / L
$3 / $3
| Institution | Action | Rating | Date |
|---|---|---|---|
Needham | Downgraded | Buy → Hold | 2026-05-04 |
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-05-01 |
Citizens | Reiterated | Market Outperform | 2026-03-13 |
Goldman Sachs | Reiterated | Neutral | 2025-04-17 |
Citizens Capital Markets | Reiterated | Market Outperform | 2025-03-05 |
JMP Securities | Reiterated | Market Outperform | 2025-02-11 |
B of A Securities | Downgraded | Neutral → Underperform | 2024-06-20 |
Morgan Stanley | Reiterated | Equal Weight | 2023-03-20 |
Credit Suisse | Upgraded | Underperform → Neutral | 2023-03-07 |
JP Morgan | Reiterated | Neutral | 2023-02-27 |
Northland Capital Markets | Reiterated | Market Perform | 2021-05-05 |
Stifel | Downgraded | Buy → Hold | 2021-05-05 |
Jefferies | Downgraded | Buy → Hold | 2021-02-12 |
Citigroup | Upgraded | Neutral → Buy | 2020-03-17 |
Northland Securities | Downgraded | Outperform → Market Perform | 2020-02-24 |
Stifel Nicolaus | Reiterated | Buy | 2019-09-18 |
BTIG Research | Reiterated | Buy | 2018-10-16 |
Deutsche Bank | Reiterated | Buy | 2018-05-03 |
Bank of America | Downgraded | Buy → Underperform | 2018-05-02 |
Chardan Capital | Reiterated | Neutral | 2018-03-27 |
UBS | Reiterated | Neutral | 2018-02-21 |
Wallachbeth | Reiterated | Hold | 2016-07-05 |
Lake Street | Reiterated | Buy | 2016-06-29 |
RBC Capital | Downgraded | Outperform → Sector Perform | 2016-06-29 |
Barclays | Downgraded | Overweight → Equal Weight | 2016-06-29 |
One row per institution, most recent rating